ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

BDSI: Biodelivery Sciences Intl Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

BIODELIVERY SCIENCES INTL INC (NASD)
BDSI	4.08	N/A	(N/A%)	Vol. 0	N/A ET

BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any process, substance, or combination thereof, that delivers drugs into the body.

General Information

BIODELIVERY SCI

801 Corporate Center Drive Suite #210 Raleigh, NC 27607 Phone: 919 582-9050 Fax: 919 582-9051 Web: www.bdsinternational.com Email: michael.russell@fdashtonpartners.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	12/06/2009

Price and Volume Information

Zacks Rank
Yesterday's Close	4.08
52 Week High	8.29
52 Week Low	2.11
Beta	0.88
20 Day Moving Average	123,799.20
Target Price Consensus	8.06

% Price Change
4 Week	-7.21
12 Week	-17.43
YTD	42.07

% Price Change Relative to S&P 500
4 Week	-8.21
12 Week	-22.16
YTD	17.58

Share Information
Shares Outstanding (millions)	21.00
Market Capitalization (millions)	86.52
Short Ratio	4.04
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.19
Current Year EPS Consensus Estimate	1.55
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	12/06/2009

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	2.66
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-30.77%
vs. Previous Quarter	29.17%

Sales Growth
vs. Previous Year	-88.32%
vs. Previous Quarter:	-66.90%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-
06/30/09	-
03/31/09	-

ROA
09/30/09	-75.05
06/30/09	-103.43
03/31/09	-94.36

Current Ratio
09/30/09	0.35
06/30/09	0.10
03/31/09	0.06

Quick Ratio
09/30/09	0.35
06/30/09	0.10
03/31/09	0.06

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	3,930.52
06/30/09	4,256.15
03/31/09	-11,925.47

Pre-Tax Margin
09/30/09	3,930.52
06/30/09	4,256.15
03/31/09	-11,925.47

Book Value
09/30/09	-1.96
06/30/09	-1.97
03/31/09	-1.96

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research